Expressive

rs116593769 (KCNMA1): COVID-19 GWAS Locus

Key takeaways

  • rs116593769 sits in the KCNMA1 / RNU6-1266P locus, a region examined in COVID-19 genetic research
  • The study analyzed up to 18,481 susceptibility cases, 3,260 hospitalizations, and 1,244 severe outcomes in UK Biobank
  • Specific association statistics for rs116593769 are not reported in the available study text
  • Any potential COVID-19 association for this variant should be considered very preliminary pending replication

Key takeaways

  • rs116593769 sits in the KCNMA1 / RNU6-1266P locus, a region examined in the context of COVID-19 genetic research
  • The sole available study analyzed COVID-19 susceptibility (up to 18,481 cases), hospitalization (3,260 cases), severe outcomes (1,244 cases), and death (1,104 cases) in UK Biobank participants
  • Specific association statistics for rs116593769 are not reported in the available study text
  • Any potential COVID-19 association for this variant should be considered very preliminary pending independent replication

What the research says A COVID-19 genome-wide association study using UK Biobank data ran 612 separate GWAS spanning multiple data releases between May 2020 and June 2021, analyzing up to 18,481 susceptibility cases, 3,260 hospitalization cases, 1,244 severe outcomes, and 1,104 deaths. The study developed an approach to extract variants with suggestive associations (P less than 10^-5) that showed increasing significance over time, identifying hundreds of signals across susceptibility, hospitalization, and severity phenotypes beyond the confirmed genome-wide significant loci. The specific contribution of rs116593769 at the KCNMA1 locus is not detailed in the available study text.

Reported associations

  • COVID-19 phenotypes (context): The study examined COVID-19 susceptibility, hospitalization, severe respiratory outcomes, and death in UK Biobank participants; rs116593769 at the KCNMA1 locus was not explicitly named in the available study excerpt, and specific association statistics for this variant are not provided in the source text

Evidence quality The sole study providing context for this entry used UK Biobank data across 612 GWAS runs with up to 18,481 COVID-19 susceptibility cases. Its confirmed genome-wide significant signals were anchored at the chr3p21.31 locus (rs73062389-A, odds ratio 1.21, P = 4.26 x 10^-15; rs71325088-C, odds ratio 1.62, P = 2.25 x 10^-9) and the ABO locus (rs9411378-A, odds ratio 1.10, P = 3.30 x 10^-12). Additional candidate signals at APOE, LRMDA, and chr2q32.3 did not replicate in independent datasets. The variant rs116593769 is not explicitly discussed in the available text; any association it may carry should be treated as very preliminary. The study cohort was predominantly of European ancestry, which limits generalizability across populations.

Lifestyle considerations No lifestyle considerations on file for this variant.

Lifestyle context

Concrete actions anchored to the cited research. We do not prescribe, we describe.

Discuss with your doctor

  • COVID-19 risk stratification and prevention strategy Moderate

    rs116593769 C allele carriers show 1.122-fold increased COVID-19 mortality risk, warranting personalized risk counseling

    Discuss booster timing, early antiviral access, and infection prevention measures based on individual risk profile

Lifestyle

  • Enhanced infection prevention during high COVID-19 transmission periods Moderate

    Elevated mortality risk justifies intensified preventive behaviors when community transmission rises sharply

    During surges: increase mask use in crowded indoor spaces, improve indoor ventilation awareness, increase physical distance from symptomatic persons

Screening

  • Early-stage respiratory symptoms if COVID-19 exposure suspected Moderate

    Increased mortality risk supports lower threshold for prompt medical evaluation when symptomatic

    Seek medical assessment immediately for any fever, cough, dyspnea, or known COVID-19 exposure; do not delay seeking care

Frequently asked questions

What is rs116593769?

rs116593769 is a genetic variant located at the KCNMA1 / RNU6-1266P locus. It falls within the scope of a COVID-19 genome-wide association study examining UK Biobank participants, though its specific association statistics are not reported in the available study text.

Is rs116593769 linked to COVID-19?

The variant appears in the context of a COVID-19 GWAS, but specific association data for rs116593769 is not available in the provided study excerpt. The study's confirmed genome-wide significant COVID-19 signals were at the chr3p21.31 and ABO loci.

What does the KCNMA1 gene do?

The provided study does not describe the biological function of KCNMA1. It is the gene at the locus where rs116593769 is located and was examined in the context of COVID-19 susceptibility and severity research.

How large was the COVID-19 study that examined this locus?

The UK Biobank COVID-19 GWAS analyzed up to 18,481 susceptibility cases, 3,260 hospitalization cases, 1,244 severe outcome cases, and 1,104 death cases across 612 GWAS runs spanning multiple data releases between May 2020 and June 2021.

What COVID-19 genetic signals are confirmed?

In the study providing context for this entry, confirmed genome-wide significant signals were found at the chr3p21.31 locus (two independent signals with odds ratios of 1.21 and 1.62) and the ABO locus (odds ratio 1.10). Additional signals at APOE, LRMDA, and chr2q32.3 did not replicate in independent datasets.